Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Organogenesis (ORGO : NSDQ)

• Company Description    Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Number of Employees: 869

• Price / Volume Information    Yesterday's Closing Price: $5.63 Daily Weekly Monthly 20 Day Moving Average: 2,347,001 shares Shares Outstanding: 126.86 (millions) Market Capitalization: $714.21 (millions) Beta: 1.68 52 Week High: $6.71 52 Week Low: $2.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 42.17% 38.45% 12 Week 19.03% 14.09% Year To Date 75.94% 53.79%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 85 Dan Road - Canton,MA 02021 USA ph: 781-575-0775 fax: - organoir@westwicke.com http://www.organogenesis.com

• General Corporate Information    Officers Gary S. Gillheeney, Sr. - Chairman; Chief Executive Officer and President David Francisco - Chief Financial Officer Alan A. Ades - Director Robert Ades - Director Michael J. Driscoll - Director Peer Information Organogenesis (GSAC) Organogenesis (CASI) Organogenesis (ALCD.) Organogenesis (OMNN) Organogenesis (CGPI.) Organogenesis (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 68621F102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 126.86 Most Recent Split Date: (:1) Beta: 1.68 Market Capitalization: $714.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.80 Price/Cash Flow: 26.98 Price / Sales: 1.54 EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: 300.00% Sales Growth vs. Year Ago Period: 30.98% vs. Previous Quarter: 49.36% ROE 09/30/25 - 4.01 06/30/25 - -0.37 03/31/25 - -4.00 ROA 09/30/25 - 2.06 06/30/25 - -0.20 03/31/25 - -2.26 Current Ratio 09/30/25 - 3.32 06/30/25 - 3.95 03/31/25 - 4.12 Quick Ratio 09/30/25 - 2.88 06/30/25 - 3.45 03/31/25 - 3.67 Operating Margin 09/30/25 - 2.14 06/30/25 - -0.22 03/31/25 - -2.28 Net Margin 09/30/25 - -1.30 06/30/25 - -1.92 03/31/25 - -3.46 Pre-Tax Margin 09/30/25 - -1.33 06/30/25 - -5.01 03/31/25 - -5.29 Book Value 09/30/25 - 2.01 06/30/25 - 1.84 03/31/25 - 1.91 Inventory Turnover 09/30/25 - 3.70 06/30/25 - 3.78 03/31/25 - 4.05 Debt-to-Equity 09/30/25 - 0.01 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 34.26 06/30/25 - 35.45 03/31/25 - 0.17

Powered by Zacks Investment Research ©